New Episodes and Suicidal Risks in Bipolar and Major Depressive Disorder Patients During Versus Before Long-Term Treatment With Lithium

IF 5 2区医学 Q1 PSYCHIATRY

Acta Psychiatrica Scandinavica Pub Date : 2025-07-01 DOI:10.1111/acps.70002

Maurizio Pompili, Isabella Berardelli, Salvatore Sarubbi, Elena Rogante, Mariarosaria Cifrodelli, Denise Erbuto, Dorian A. Lamis, Ross J. Baldessarini

{"title":"New Episodes and Suicidal Risks in Bipolar and Major Depressive Disorder Patients During Versus Before Long-Term Treatment With Lithium","authors":"Maurizio Pompili, Isabella Berardelli, Salvatore Sarubbi, Elena Rogante, Mariarosaria Cifrodelli, Denise Erbuto, Dorian A. Lamis, Ross J. Baldessarini","doi":"10.1111/acps.70002","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Lithium treatment reduces the risk of recurring episodes in bipolar disorder (BD) and probably also in major depressive disorder (MDD) and has evidence of antisuicidal effects. Study objectives were to test for effects of adding lithium treatment for one year to a year of other treatments on risks of illness recurrence, suicidal ideation, and suicide attempts.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We compared 296 major mood disorder outpatients for 12 months with treatment that did not include lithium versus 12 months with lithium included. We considered differences in the recurrence of new episodes of illness, new suicidal ideation and suicide attempts, and estimated time to these outcomes with survival analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>With lithium treatment included, there were marked reductions in episode recurrences (3.12-fold), suicidal ideation (4.78-fold), and suicide attempts (6.54-fold) in both BD and MDD patients, with corresponding delays to these outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Adding lithium treatment was strongly associated with reduced risk and delay of clinical recurrence, suicidal ideation and suicide attempts in both BD and MDD outpatients.</p>\n </section>\n </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"152 4","pages":"290-298"},"PeriodicalIF":5.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.70002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Psychiatrica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/acps.70002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Lithium treatment reduces the risk of recurring episodes in bipolar disorder (BD) and probably also in major depressive disorder (MDD) and has evidence of antisuicidal effects. Study objectives were to test for effects of adding lithium treatment for one year to a year of other treatments on risks of illness recurrence, suicidal ideation, and suicide attempts.

Methods

We compared 296 major mood disorder outpatients for 12 months with treatment that did not include lithium versus 12 months with lithium included. We considered differences in the recurrence of new episodes of illness, new suicidal ideation and suicide attempts, and estimated time to these outcomes with survival analyses.

Results

With lithium treatment included, there were marked reductions in episode recurrences (3.12-fold), suicidal ideation (4.78-fold), and suicide attempts (6.54-fold) in both BD and MDD patients, with corresponding delays to these outcomes.

Conclusions

Adding lithium treatment was strongly associated with reduced risk and delay of clinical recurrence, suicidal ideation and suicide attempts in both BD and MDD outpatients.

Abstract Image

查看原文本刊更多论文

长期锂离子治疗前后双相情感障碍和重度抑郁症患者的新发作和自杀风险

锂离子治疗可降低双相情感障碍（BD）和重度抑郁症（MDD）复发的风险，并有证据表明其具有抗自杀作用。研究目的是测试在治疗中加入锂治疗一年或其他治疗一年对疾病复发、自杀意念和自杀企图风险的影响。方法：我们比较了296例重度情绪障碍门诊患者12个月不含锂治疗和12个月含锂治疗。我们考虑了新发病、新自杀意念和自杀企图的复发率的差异，并通过生存分析估计这些结果的时间。结果包括锂治疗在内，BD和MDD患者的发作复发率（3.12倍）、自杀意念（4.78倍）和自杀企图（6.54倍）均显著降低，这些结果相应延迟。结论在BD和MDD门诊患者中，添加锂治疗与降低临床复发、自杀意念和自杀企图的风险和延迟密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Psychiatrica Scandinavica 医学-精神病学

CiteScore

11.20

自引率

3.00%

发文量

135

审稿时长

6-12 weeks

期刊介绍： Acta Psychiatrica Scandinavica acts as an international forum for the dissemination of information advancing the science and practice of psychiatry. In particular we focus on communicating frontline research to clinical psychiatrists and psychiatric researchers. Acta Psychiatrica Scandinavica has traditionally been and remains a journal focusing predominantly on clinical psychiatry, but translational psychiatry is a topic of growing importance to our readers. Therefore, the journal welcomes submission of manuscripts based on both clinical- and more translational (e.g. preclinical and epidemiological) research. When preparing manuscripts based on translational studies for submission to Acta Psychiatrica Scandinavica, the authors should place emphasis on the clinical significance of the research question and the findings. Manuscripts based solely on preclinical research (e.g. animal models) are normally not considered for publication in the Journal.